

SMid Growth Portfolio

Commentary | 2Q26 | Managed Accounts

Highlights

- The Russell 2500 Growth Index (the “Index”) returned 24.0% in 2Q26, its strongest quarter since 2020, driven by high-beta stocks and technology companies.
- The Congress SMid Growth Portfolio (the “Portfolio”) delivered absolute returns of 18.8% (net of fees) but trailed the Index as positive relative performance in Industrials was offset by Health Care and Information Technology.
- The Portfolio underperformed in April and May, which saw concentrated Index leadership with only 30% of stocks ahead of the Index, but outperformed by 370 bps (net of fees) in June as market participation broadened and the beta-led rally moderated.
- One-year relative performance comparisons were pressured by the significant low-quality rally in 2025; in the second half of 2025 non-earning companies in the Index outperformed companies with earnings by almost 30%.
- Since inception, the Portfolio has a 96% up capture and 81% down capture (gross of fees*) and has compounded capital 3.6x (net of fees) vs 2.8x for the Index.
- The Portfolio has outperformed the Index (net of fees) in 71% of rolling 1-year periods by an average of 717 bps, 89% of rolling 3-year periods by 670 bps, and 100% of rolling 5-year periods by 629 bps.

Portfolio Review

- The Index posted its best quarter since 2020, reversing sharply from 1Q26 as risk-on sentiment returned amid resilient corporate earnings and expectations for a resolution to the Iran conflict. The highest-beta quintile of the Index rose 59%, while Technology advanced 47%, driven by a 117% surge in semiconductors. The Portfolio lagged in April and May as leadership narrowed – just 30% of Index constituents outperformed during the beta-driven rally. In June, the beta trade moderated and market participation broadened, and the Portfolio outperformed. For the full quarter, the Portfolio delivered a strong absolute return in a challenging environment for relative performance.
- Industrials was the largest contributor to quarterly returns. Sterling Infrastructure rallied after reporting 92% year-over-year revenue growth. Carpenter Technology, a specialty alloys producer, advanced on record quarterly results and continued margin expansion, supported by aerospace, defense, and energy demand. nVent Electric, which is increasingly exposed to data center power and cooling, also delivered solid results despite elevated expectations, driven by continued data center demand. The Portfolio’s lack of exposure to Communication Services further supported relative results.
- Health Care was the largest detractor, though we believe we improved the sector holdings during the quarter. TransMedics Group, a developer of organ transplant technology, declined as industry organ donor volumes were lower than anticipated. Insulet, which was sold during the quarter, detracted as GLP-1 adoption reduced the estimated type 2 diabetes addressable market. In Technology, the Portfolio’s lack of exposure to Astera Labs weighed on relative performance as the stock benefited from AI infrastructure tailwinds. Mirion Technologies, which provides radiation detection solutions for nuclear power and medical applications, has not yet benefited from new nuclear power plant development.

Outlook

- In our view, SMid caps remain a compelling opportunity, offering the stability of mid-caps with the outsized return potential of small caps.
- Hyperscalers are expected to spend nearly \$1 trillion on AI-related capex this year, which should continue to underpin growth and trickle out into parts of the economy supporting the AI infrastructure buildout. We believe the Portfolio is well positioned to benefit from this trend and has exposure to areas of the economy with durable, long-term growth drivers.
 - The Portfolio maintains exposure to AI and AI-related capex across sectors, including Industrials (Comfort Systems, Sterling) and Technology (Credo, Rambus).
 - Curtiss-Wright and Karman are positioned to potentially benefit from increased defense spending.
 - In the Consumer sectors, we maintain exposure to the lower-end consumer (Affirm) and the resiliency of the mid-to-upper end consumer (Dutch Bros).
 - In Health Care we have “picks and shovels” exposure as several of our holdings (Repligen, Halozyme) seek to offer critical solutions to the recovering biotech industry.
- The June Russell Rebalance also brought significant changes to the Russell 2500 Growth Index. The new Index is -40% smaller by weighted average market cap and, in our view, lower quality – return on equity, margins, and free cash flow yield all declined, while biotech, an industry that historically has more unprofitable companies, increased in weight. Within biotech, we are accessing the space through a “picks and shovels” approach and seeking the profitable stocks in the industry without compromising on our principals. The Portfolio remains focused on profitable, high-quality companies with durable earnings growth, expanding free cash flow, and strong margins.

Average Annualized Performance (%) as of 6/30/2026


	QTD	YTD	1 Yr	3 Yrs	5 Yrs	Since Inception (4/1/2017)
SMid Growth Composite (Gross)	19.0	15.9	18.0	13.7	7.8	15.1
SMid Growth Composite (Net)	18.8	15.6	17.4	13.2	7.3	14.7
Russell 2500 Growth®	24.0	19.7	32.9	16.4	5.0	11.8

Past performance does not guarantee future results *Characteristics are gross of fees and are computed without the deduction of fees and expenses.

Data is as of 6/30/2026. Sources throughout this presentation: Congress Asset Management, Bloomberg, Russell Investments, and Morningstar Direct. The information throughout this presentation is for illustrative purposes and is subject to change at any time. Holdings and sector weightings are subject to change and should not be considered investment advice or a recommendation to buy or sell a particular security. Actual holdings and sector weightings may vary by client. Gross performance shown does not reflect the deduction of investment management fees and certain transaction costs, which will reduce investment performance. This information is supplemental to the GIPS Report. Performance returns of less than one year are not annualized. This managed account strategy involves risk, may not be profitable, may not achieve its objective, and may not be suitable or appropriate for all investors. Investors should consider the investment objectives, risks, and fees of this strategy carefully with their financial professional before investing. Performance is preliminary and subject to change at any time. Specific investments described herein do not represent all investment decisions made by Congress Asset Management. The reader should not assume that investment decisions identified and discussed were or will be profitable.

% Total Effect Composite vs. Index*

3/31/2026 - 6/30/2026



*Characteristics are gross of fees and are computed without the deduction of fees and expenses.

Top 5 Contributors/Detractors

Stock	Avg. Weight%
Sterling Infrastructure, Inc.	4.86
nVent Electric plc	4.73
Carpenter Technology, Corp.	3.14
Rambus, Inc.	3.83
Comfort Systems USA, Inc.	3.88

Bottom 5 Contributors/Detractors

Stock	Avg. Weight%
Karman Holdings, Inc.	2.07
TransMedics Group, Inc.	1.67
Tractor Supply Company	1.60
Insulet Corp.	0.84
Prestige Consumer Healthcare, Inc.	1.08

Sterling Infrastructure, Inc. (STRL) is a specialty infrastructure contractor that provides site development, transportation, and building solutions across end markets including data centers and semiconductor facilities. STRL reported solid first-quarter 2026 results, with combined backlog exceeding \$5.2 billion. Management highlighted favorable project timing and increasing contributions from larger, more complex e-infrastructure projects. We believe Sterling's integrated capabilities and growing exposure to data center and semiconductor campus construction support attractive long-term growth opportunities.

nVent Electric plc (NVT) provides electrical infrastructure products and systems that connect, protect, and manage power and equipment across industrial, commercial, utility, and data center applications. The company reported record sales, orders, and backlog in Q1 2026 and meaningfully raised its full-year organic growth outlook to 21%-23%, supported by data center demand and backlog visibility.

Carpenter Technology Corp. (CRS) manufactures and distributes specialty metals and alloys to the aerospace, defense, and medical industries. Supply of these materials remains constrained relative to demand, affording the company meaningful pricing power and supporting operating margin expansion. During the quarter, aerospace and defense demand accelerated sharply, with commercial aerospace structural volumes recovering and orders improving with healthy pricing dynamics. As a result, management raised its fiscal year 2026 profit and free cash flow outlook and confirmed that fiscal year 2027 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) targets were set to be revised higher.

Karman Holdings, Inc. (KRMN) designs, engineers, and manufactures mission-critical aerospace and defense systems for space launch, missile defense, maritime, and national security programs. Shares underperformed during the quarter despite management reiterating a healthy multi-year growth outlook, as valuation multiples across the defense sector compressed amid uncertainty surrounding U.S. defense funding and the timing of contract awards.

TransMedics Group, Inc. (TMDX) is a medical technology company that provides organ preservation and transportation solutions for transplant procedures. Quarterly results fell short of expectations, as industry organ donor volumes were lower than anticipated. Management indicated that the company continued to gain market share during the quarter despite the softer market backdrop. Despite these near-term headwinds, the company's market leadership, growing adoption, product innovation, and international expansion remain central to our long-term investment thesis.

Tractor Supply Company (TSCO) is a retail chain that sells farm and ranch supplies. Top-line growth has been elusive, and the company has not met its long-term growth targets since 2022. TSCO is investing in several initiatives aimed at restarting growth, but in our view, it remains unclear when these efforts will pay off, and the spending is likely to weigh on earnings in the near term. New-store productivity has also declined, and management has acknowledged that newer locations are cannibalizing sales from existing stores, suggesting TSCO may be running out of opportunities to profitably expand its store base. The stock was subsequently sold in the quarter.

Information is as of 6/30/2026. Sources: Congress Asset Management and Bloomberg. The information throughout this presentation is for illustrative purposes and is subject to change at any time. Holdings, sector weightings and securities identified as top contributors and detractors throughout this presentation are subject to change and should not be considered investment advice or a recommendation to buy or sell a particular security. Actual holdings may vary by client. The securities identified do not represent all the securities purchased, sold or recommended to clients. The reader should not assume that investment decisions identified and discussed were or will be profitable. For information regarding the methodology used to select these holdings or to obtain a list showing the contribution of every holding in the strategy's composite account, which we believe is most representative to both a current and/or prospective client, please contact us at 1-800-234-4516. Gross performance shown does not reflect the deduction of investment management fees and certain transaction costs, which will reduce investment performance. Past performance does not guarantee future results.

Portfolio Activity

Purchases	Sector	Sales	Sector
Affirm Holdings, Inc.	Financials	The Cooper Companies, Inc.	Health Care
Amneal Pharmaceuticals, Inc.	Health Care	Kinsale Capital Group, Inc.	Financials
Dutch Bros, Inc.	Consumer Discretionary	Morningstar, Inc.	Financials
DigitalOcean Holdings, Inc.	Information Technology	Prestige Consumer Healthcare, Inc.	Health Care
Samsara, Inc.	Information Technology	Penumbra, Inc.	Health Care
Krystal Biotech, Inc.	Health Care	Insulet Corporation	Health Care
Ligand Pharmaceuticals, Inc.	Health Care	Pool Corporation	Consumer Discretionary
Neurocrine Biosciences, Inc.	Health Care	PTC, Inc.	Information Technology
Plexus Corp.	Information Technology	SPS Commerce, Inc.	Information Technology
Solaris Energy Infrastructure, Inc.	Energy	Tractor Supply Company	Consumer Discretionary
TransMedics Group, Inc.	Health Care		
UMB Financial Corporation	Financials		

Affirm Holdings, Inc. (AFRM) is a financial technology company that operates a buy now, pay later platform, enabling consumers to finance purchases over time. In our view, AFRM could have a durable growth runway as it continues to gain market share, expand internationally, and pursue new financial services opportunities, including the Affirm Card.

Amneal Pharmaceuticals, Inc. (AMRX) produces generic and branded pharmaceuticals, including a growing portfolio of biosimilars, and distributes pharmaceutical products. The company's expanding biosimilars business and strategic shift toward the specialty pharmaceutical market position it for potentially attractive long-term growth.

Dutch Bros, Inc. (BROS) operates a chain of drive-thru beverage shops offering customized coffees, teas, and its proprietary line of energy drinks. Same-shop sales accelerated throughout 2025 as a new food menu, enhancements to its mobile app rewards program, and increased advertising drove higher customer traffic. The company expanded its footprint from 982 to 1,136 shops during the year and has established a long-term goal of approximately 7,000 locations, with management expecting each new shop to recover its construction costs in just over two years. We believe the market has become overly concerned about increasing competition, creating an opportunity to invest in a differentiated business with a long runway for unit growth at a valuation discount to comparable peers.

DigitalOcean Holdings, Inc. (DOCN) offers cloud computing infrastructure and managed services designed to help developers, startups, and small-to-medium-sized businesses build, deploy, and scale applications easily and affordably. The company has successfully moved upmarket by targeting larger customers with more complex workloads while expanding its AI infrastructure offerings. Investments in additional data center capacity and an expanding base of customers adopting its AI products could also support continued growth.

Samsara, Inc. (IOT) provides a cloud-based platform that connects physical operations, including vehicles, equipment, and facilities, through integrated hardware and software solutions. The company serves fleet operators and industrial customers seeking to improve safety, efficiency, and regulatory compliance. Its large, underpenetrated total addressable market and the compelling return on investment its solutions have delivered to customers could support a long runway for growth. In addition, profitability has

The Cooper Companies, Inc. (COO) is a leading provider of vision correction products, medical devices, and fertility products. The company is facing challenges in both its Vision and Surgical businesses. Within the Vision business, increased competition has resulted in market share losses and pricing pressure. The position was sold due to limited visibility into an improvement in organic growth trends.

Kinsale Capital Group, Inc. (KNSL) is a specialty insurance company focused on the U.S. excess and surplus lines market, providing property, casualty, and specialty coverage for hard-to-place risks through a technology-driven underwriting platform. Over the last several quarters, the company reported a deceleration in net written premium due to increasing competition and a softening insurance market. As a result, the position was sold.

Morningstar, Inc. (MORN) is a financial services data and research firm that provides independent investment insights, analytics, ratings, indexes, and workflow tools to investors, financial advisors, asset managers, and institutions. The position was sold because advances in artificial intelligence could pressure Morningstar's business by reducing the durability of seat growth and weakening the pricing power of its subscription- and license-based offerings.

Prestige Consumer Healthcare, Inc. (PBH) markets a portfolio of niche, market-leading over-the-counter consumer healthcare brands through an asset-light model focused on brand management, cash generation, and bolt-on acquisitions. We exited the position as continued delays in the recovery of the Eye Care segment reduced our confidence in Prestige's ability to reaccelerate organic growth. In addition, as acquisitions became an increasingly important driver of growth, we viewed the investment thesis as less compelling relative to other opportunities.

Penumbra, Inc. (PEN) is a leading provider of medical devices for mechanical thrombectomy and embolization procedures. We sold the position ahead of Boston Scientific's expected acquisition because we believed Penumbra's share price would primarily reflect the value of the proposed transaction rather than the company's underlying fundamentals, making the investment less compelling, in our view.

Insulet Corp. (PODD) is a medical device company that develops patch insulin delivery systems for people with diabetes. Competition in the

Specific investments mentioned should not be considered recommendations. The reader should not assume that investment decisions identified and discussed were or will be profitable.

improved as management has realized efficiency gains and economies of scale.

Krystal Biotech, Inc. (KRY) is a biopharmaceutical company with a proprietary gene therapy platform. We believe the company's pipeline and upcoming catalysts support a favorable long-term growth outlook. Those catalysts include multiple late-stage clinical trial readouts and the international launch of Vyjuvek.

Ligand Pharmaceuticals, Inc. (LGND) is a biopharmaceutical royalty company that provides capital and technologies to biopharmaceutical companies to support the discovery and development of new medicines. Ligand's diversified and expanding royalty portfolio positions the company for long-term growth, in our view.

Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. We view the company's robust pipeline and increasing adoption of its two most recently launched products as key drivers of its favorable long-term growth outlook.

Plexus Corp. (PLXS) is an electronics manufacturing services company with significant exposure to semiconductor capital equipment and defense electronics, two end markets that have benefited from favorable trends. Recent results reflected strong execution, highlighted by robust demand in semiconductor capital equipment, better-than-expected defense revenue, and a third consecutive increase in full-year guidance. The company has also been supported by a record manufacturing funnel and a growing defense backlog.

Solaris Energy Infrastructure, Inc. (SEI) is an energy infrastructure company that provides modular power generation solutions to data centers as well as logistics equipment and services to upstream and midstream energy operators. We view SEI's successful pivot into the behind-the-meter power market as positioning the company to capitalize on strong demand, supported by market capacity constraints and its first-mover advantage.

TransMedics Group, Inc. (TMDX) is a medical technology company whose products are used throughout the organ transplant process. We view the company as poised for continued growth, driven by increasing adoption of its technology, ongoing innovation, and international expansion. As an industry leader, its products have the potential to transform the transplant market by increasing the number of transplants performed and improving patient outcomes.

UMB Financial Corp. (UMBF) is a diversified financial services company that provides commercial banking, personal banking, wealth management, asset servicing, and institutional banking solutions to business, retail, government, and institutional clients. We expect that UMBF's relatively high-fee income mix and defensive business profile may help offset the risk of our more cyclical financial holdings.

insulin pump market is increasing. Additionally, a key growth driver for the company has been the adoption of insulin pumps by people with Type 2 diabetes, but that opportunity may be diminished as GLP-1 medications become more widely adopted.

POOL Corp. (POOL) is a wholesale distributor of swimming pool supplies, equipment, and related leisure products serving pool builders, retailers, and service companies. The company has not achieved its 6–9% revenue growth target since 2022, as higher interest rates and inflation have weighed on demand for new pool construction and renovations, which together account for more than one-third of sales. Competition has also intensified, with Heritage Pool Supply increasing its share of the pool distribution market from 10% to more than 15% through acquisitions of local distributors and aggressive pricing. These competitive pressures, combined with a soft housing backdrop, make a return to the company's prior growth and margin profile unlikely in the near term.

PTC, Inc. (PTC) offers software solutions that drive efficiencies in the way physical products are engineered, manufactured, and serviced. We sold the position due to slowing growth with no catalysts on the horizon, significant management turnover, changes to its sales organization, and a premium valuation that presented downside risk, in our view.

SPS Commerce, Inc. (SPSC) offers cloud-based supply chain management solutions. The position was sold due to slowing customer growth, downward pressure on margins from declining wallet share, and significant management turnover.

Tractor Supply Company (TSCO) is a retail chain that sells farm and ranch supplies, pet food, tools, clothing, and lawn equipment. Revenue growth has been difficult to sustain, and the company has fallen short of its long-term growth targets since 2022. Tractor Supply is investing in several initiatives aimed at reigniting growth, but in our view, it remains unclear when these efforts will generate meaningful returns, and the associated spending is likely to weigh on earnings in the near term. New-store productivity has also declined, and management has acknowledged that newer locations are cannibalizing sales from existing stores, leading us to believe the company may have fewer opportunities to profitably expand its store base.

Specific investments mentioned should not be considered recommendations. The reader should not assume that investment decisions identified and discussed were or will be profitable.

The Russell 2500 Growth Index measures the performance of those Russell 2500® Index companies with higher price-to-book ratios and higher forecasted growth values. Indices are unmanaged, do not reflect fees and expenses and are not available for direct investment. **Upside Capture ratio** measures the manager's overall performance to the benchmark's overall performance, considering only months that are positive in the benchmark. An Upside Capture Ratio of more than 100% indicates a manager who outperforms the relative benchmark in the benchmark's positive months. **Downside Capture ratio** is the ratio of the manager's overall performance to the benchmark's overall performance, considering only months that are negative in the benchmark. A Downside Capture Ratio of less than 100% indicates a manager who outperforms the relative benchmark in the benchmark's negative months and protects more of a portfolio's value during down markets. **Return on Equity** is equal to a company's net income for a full fiscal year, divided by total shareholder equity. **The Forward P/E Ratio**, or forward price-to-earnings ratio, is a valuation metric that divides a company's current stock price by its estimated earnings per share (EPS) for the next 12 months. It provides an indication of how much investors are willing to pay for each dollar of a company's projected future earnings. **Standard Deviation** is a measure of the dispersion of a set of data from its mean. It is used by investors as a gauge for the amount of expected volatility. **Return on Equity** is equal to a company's net income for a full fiscal year, divided by total shareholder equity. **Free Cash Flow** is the money a company has left over after paying its operating expenses (OpEx) and capital expenditures (CapEx).

Congress Asset Management Co. SMid Growth Composite 4/1/2017 – 12/31/2025

Year	Total Return Gross of Fees%	Total Return Net of Fees%	Russell 2500 Growth Return % (dividends reinvested)	Composite Gross 3-Yr annualized ex- post St Dev (%)	Russell 2500 Growth 3-Yr annualized ex- post St Dev (%)	Number of Portfolios	Gross Disper- sion %	Total Com- posite Assets End of Period (\$ millions)	Total Firm Discretionary Assets End of Period (\$ millions)	Total Firm Advisory-Only Assets End of Period (\$ millions)	Total Firm Assets End of Period # (\$ millions)
2025	6.2	5.7	10.3	17.4	18.8	460	0.36	672	14,199	9,000	23,199
2024	13.0	12.4	13.9	21.4	22.8	280	0.57	400	14,207	9,471	23,678
2023	18.8	18.3	18.9	19.8	21.0	195	0.56	173	12,146	8,514	20,660
2022	-21.5	-21.7	-26.2	22.8	25.2	158	0.51	96	10,083	6,799	16,882
2021	28.4	27.9	5.0	18.5	22.0	98	0.91	79	12,778	8,018	20,796
2020	50.3	49.7	40.5	20.7	23.9	47	0.62	55	10,746	5,523	16,269
2019	28.7	28.2	32.7	n/a	n/a	14	n/a	37	8,445	4,083	12,528
2018	1.3	0.9	-7.5	n/a	n/a	≤5	n/a	27	7,102	3,132	10,234
3/31/17– 12/31/17	12.8	12.5	17.1	n/a	n/a	≤5	n/a	35	7,272	3,274	10,546

#The "Total Firm Assets" column includes unified managed account (UMA) assets

Congress Asset Management claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. Congress Asset Management has been independently verified for the periods 1/1/96 – 12/31/25. The verification report(s) is/are available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedure for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

Firm Information: Congress Asset Management Co. (CAM) is an investment advisor registered with the Securities and Exchange Commission under the Investment Advisers Act of 1940. Registration does not imply a certain level of skill or training. CAM manages a variety of public equity, private equity, fixed income, and ETF managed portfolios for private and institutional clients. CAM acquired Prelude Asset Management, LLC on March 15, 2010. CAM merged with Congress Capital Partners, LLP on June 30, 2015. CAM acquired certain strategies of Century Capital Management, LLC on September 15, 2017.

Composite Characteristics: The creation and inception date of the SMid Growth Composite is April 1, 2017, which reflects the first full month an account was fully invested in the strategy and met the inclusion criteria. The composite includes all fully discretionary portfolios with a value over \$100 thousand (US dollars) managed in the SMid growth style for a minimum of one full month. The SMid growth strategy invests in the equity of high-quality companies with market capitalizations between \$300 million and \$20 billion (at the time of purchase) exhibiting consistent earnings growth. Accounts with wrap commissions are excluded from the composite. The primary composite benchmark is the Russell 2500 Growth Index. The benchmark returns are not covered by the report of the independent verifiers. Closed account data is included in the composite as mandated by the standards in order to eliminate a survivorship bias. A list of composite descriptions, a list of broad distribution pooled funds, and a list of limited distribution pooled fund descriptions are available upon request.

Calculation Methodology: Valuations and returns are computed and stated in U.S. dollars. Gross of fees returns are calculated gross of management and custodial fees and net of transaction costs. Net of fees returns are calculated using actual management fees. The composite results portrayed reflect the reinvestment of dividends, capital gains, and other earnings when appropriate. Accruals for equity securities are included in calculations. Internal dispersion is calculated using the asset-weighted standard deviation of annual gross-of-fees returns of those portfolios that were included in the composite for the entire year. For those years when less than six portfolios were included in the composite for the full year, no dispersion measure is presented. The three-year annualized ex-post standard deviation measures the variability of the composite, and the benchmark returns over the preceding 36-month period. It is not presented for periods prior to 2020 because 36-month returns were not available.

Fee Schedule: The firms' individual account fee schedule is as follows: 1.00% for first \$1 million, 0.80% for next \$4 million, 0.60% for next \$5 million. Management fees for individual accounts with assets under management exceeding \$10 million, and for institutional accounts are negotiated. The individual account fee schedule may be subject to negotiation where circumstances warrant. As fees are deducted quarterly, the compounding effect will increase the impact of the fees by an amount directly related to the gross account performance. For example, an account earning a 10% annual gross return with a 1% annual fee deducted quarterly would earn an 8.9% annual net return due to compounding.

Other Disclosures: Policies for valuing investments, calculating performance, and preparing GIPS Reports are available upon request. Past performance does not guarantee future results. This performance report should not be construed as a recommendation to purchase or sell any particular securities held in composite accounts. Market conditions can vary widely over time and can result in a loss of portfolio value. GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

Important Disclosure

Not an Offer, Recommendation or Professional Advice: This document does not constitute advice or a recommendation or offer to sell or a solicitation to deal in any security or financial product. It is provided for information purposes only and on the understanding that the recipient has sufficient knowledge and experience to be able to understand and make their own evaluation of the proposals and services described herein, any risks associated therewith and any related legal, tax, accounting or other material considerations. To the extent that the reader has any questions regarding the applicability of any specific issue discussed above to their specific portfolio or situation, prospective investors are encouraged to contact Congress Asset Management or consult with the professional advisor of their choosing.

Use of Third-Party Information: Certain information contained herein has been obtained from third party sources and such information has not been independently verified by Congress Asset Management. No representation, warranty, or undertaking, expressed or implied, is given to the accuracy or completeness of such information by Congress Asset Management or any other person. While such sources are believed to be reliable, Congress Asset Management does not assume any responsibility for the accuracy or completeness of such information. Congress Asset Management does not undertake any obligation to update the information contained herein as of any future date.

Currentness: Except where otherwise indicated, the information contained in this presentation is based on matters as they exist as of the date of preparation of such material and not as of the date of distribution or any future date. Recipients should not rely on this material in making any future investment decision

Benchmarks: Any indices and other financial benchmarks shown are provided for illustrative purposes only, are unmanaged, reflect reinvestment of income and dividends and do not reflect the impact of advisory fees. Investors cannot invest directly in an index. Comparisons to indexes have limitations because indexes have volatility and other material characteristics that may differ from a particular fund or strategy. For example, a hedge fund may typically hold substantially fewer securities than are contained in an index.

Forward-Looking Statements: Certain information contained herein constitutes "forward-looking statements," which can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "project," "estimate," "intend," "continue," or "believe," or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events, results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements. Nothing contained herein may be relied upon as a guarantee, promise, assurance or a representation as to the future.

Small-Capitalization Investing Risk: The securities of small-capitalization companies may be more vulnerable to adverse issuer, market, political, or economic developments than securities of large- or mid-capitalization companies. The securities of small-capitalization companies generally trade in lower volumes and are subject to greater and more unpredictable price changes than large- or mid-capitalization stocks or the stock market as a whole. There is typically less publicly available information concerning smaller-capitalization companies than for larger, more established companies.

Mid-Capitalization Investing Risk: The securities of mid-capitalization companies may be more vulnerable to adverse issuer, market, political, or economic developments than securities of large-capitalization companies. The securities of mid-capitalization companies generally trade in lower volumes and are subject to greater and more unpredictable price changes than large capitalization stocks or the stock market as a whole.

Growth Style Investment Risk: Growth stocks may lose value or fall out of favor with investors. Growth stocks may be more sensitive to changes in current or expected earnings than the prices of other stocks.

Equity Securities Risk: The price of equity securities may rise or fall because of economic or political changes or changes in a company's financial condition, sometimes rapidly or unpredictably. These price movements may result from factors affecting individual companies, sectors or industries selected for the Strategy's portfolio or the securities market as a whole, such as changes in economic or political conditions.

Foreign Investment Risk: Foreign securities involve increased risks due to political, social and economic developments abroad, as well as due to differences between U.S. and foreign regulatory practices. When the Strategy invests in ADRs as a substitute for an investment directly in the underlying foreign shares, the Strategy is exposed to the risk that the ADRs may not provide a return that corresponds precisely with that of the underlying foreign shares.

Sector-Focus Risk: Investing a significant portion of the Strategy's assets in one sector of the market exposes the Strategy to greater market risk and potential monetary losses than if those assets were spread among various sectors.

General Market Risk: Economies and financial markets throughout the world are becoming increasingly interconnected, which increases the likelihood that events or conditions in one country or region will adversely impact markets or issuers in other countries or regions. Securities in the Strategy's portfolio may underperform in comparison to securities in the general financial markets, a particular financial market, or other asset classes due to a number of factors, including: inflation (or expectations for inflation); deflation (or expectations for deflation); interest rates; global demand for particular products or resources; natural disasters or events; pandemic diseases; terrorism; regulatory events; other governmental trade or market control programs and related geopolitical events. In addition, the value of the Strategy's investments may be negatively affected by the occurrence of global events such as war, terrorism, environmental disasters, natural disasters or events, country instability, and infectious disease epidemics or pandemics.

Management Risk: The Strategy is actively-managed and may not meet its investment objective based on the Advisor's success or failure to implement investment strategies for the Strategy.